Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Transgenomic, Inc. (TBIO) Unlocking the Power of Non-Invasive Liquid Biopsies with ICE-COLD PCR™ Technology

Transgenomic, Inc. (NASDAQ: TBIO) is a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through progressive diagnostic technologies, such as its revolutionary ICE-COLD PCR™ (MX-ICP). Through this technology, the company provides more sensitive and accurate mutation detection without major costs or impact to current processes.

In May, Transgenomic built on the versatility of its MX-ICP platform through the launch of a novel epidermal growth factor receptor (EGFR) CLIA test for mutation detection in cancer patients, effectively opening the door for more informed diagnoses, better treatment decisions and ongoing patient monitoring moving forward. The first tests using this platform were for the detection of EGFR T790M mutations, which have been linked to patient resistance of current non-small cell lung cancer (NSCLC) treatment options.

“Launching our multiplexed ICE COLD-PCR-based CLIA mutation detection service for oncologists and their patients is a major milestone for Transgenomic and, we believe, an important advance for the field of precision medicine,” Paul Kinnon, president and chief executive officer of Transgenomic, stated in a news release. “The unsurpassed accuracy of MX-ICP and its ability to produce highly sensitive and accurate results from small amounts of almost any type of patient sample, especially liquid biopsies, allows broad use.”

MX-ICP has been shown effective in the detection of mutation with a range of biofluid samples – including blood, plasma, serum, urine, sputum and bronchial lavage – allowing for highly accurate, non-invasive diagnostics of all known and unknown mutations.

In recent months, Transgenomic has leveraged the considerable market for its diagnostic technologies and clinical and research services to record improved financial results. During the first quarter of 2015, the company’s net sales were recorded at a 4 percent year-over-year increase, with laboratory services sales increasing by over 30 percent for the same period.

“The company made good progress in the first quarter in strengthening our historical businesses while preparing for the imminent launch of our breakthrough technology: Multiplexed ICE-COLD PCR™,” continued Kinnon. “We achieved a double digit percentage increase in overall net sales excluding the divested Surveyor product line, including a robust 32 percent increase in the critical laboratory services segment.”

Moving forward, look for Transgenomic to continue building on its recent progress in order to maximize industry growth. For prospective investors, continued industry adoption of the company’s MX-ICP technology could provide ample opportunity to realize sustainable returns in the years to come.

For more information, visit

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.